Today's Date
DSG3-CAART for anti-DSG3 pemphigus vulgaris
(
CAB-101
)
ITN Protocol #:
ITN830AI
Branded Name:
CAB-101
Treatment Protocol #:
Therapeutic Area:
Autoimmune Disease
Current Status:
Enrollment
Summary:
A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris
Clinical Operations Manager
ITN Biologist
Study Personnel:
